Moderna, Inc.
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna U.S. retail pharmacy COVID-19 fall season vaccination by Year
U.S. retail pharmacy COVID-19 fall season vaccination market share (%) (%)
Moderna U.S. retail pharmacy COVID-19 fall season vaccination: 42.0% in FY2025, up 2.0 pts from a year earlier.
Where the FY2025 figure comes from
“Our COVID retail market share is 42%, up 2 percentage points from last year.”
Source: Q3 2025 Earnings Call Transcript ↗
Reported in Form 8-K Earnings Releases, DEF 14A Proxy Statement & Q3 2025 Earnings Call.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | U.S. retail pharmacy COVID-19 fall season vaccination market share (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 42.0% | +2.0 pts | Q3 2025 Earnings Call Transcript ↗ |
| FY2024 | Dec 31, 2024 | 40.0% | -8.0 pts | Q3 2024 Earnings Release (8-K) ↗ |
| FY2023 | Dec 31, 2023 | 48.0% | +11.0 pts | 2024 Proxy Statement (DEF 14A) ↗ |
| FY2022 | Dec 31, 2022 | 37.0% | – | Q4 2023 Earnings Release (8-K) ↗ |
Cite this data
StockData. (2026). Moderna U.S. retail pharmacy COVID-19 fall season vaccination (%), annual FY2022–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/us-retail-covid-share
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.